TWIST1, A novel androgen-regulated gene, is a target for NKX3-1 in prostate cancer cells by Eide, Turid et al.
PRIMARY RESEARCH Open Access
TWIST1, A novel androgen-regulated gene, is a
target for NKX3-1 in prostate cancer cells
Turid Eide1*, Håkon Ramberg1, Carlotta Glackin3, Donald Tindall4 and Kristin Austlid Taskén1,2
Abstract
Background: TWIST1 plays a key role in EMT-mediated tumor invasion and metastasis. Since bone metastasis is a
hallmark of advanced prostate cancer and is detected in at least 85% of patients who die of this disease, it is of
great importance to understand the regulation of the cellular signaling pathways involved in the metastatic process.
Methods: Prostatic cell lines were analyzed using real time RT-PCR, chromatin immunoprecipitations (ChIP) and
transfection of siRNA’s and reporter constructs.
Results: We report in this paper that TWIST1 is an androgen-regulated gene under tight regulation of NKX3-1.
Androgens repress the expression of TWIST1 via NKX3-1, which is a prostate–specific tumor suppressor that is down-
regulated in the majority of metastatic prostate tumors. We show that NKX3-1 binds to the TWIST1 promoter and
that NKX3-1 over-expression reduces the activity of a TWIST1 promoter reporter construct, whereas NKX3-1 siRNA
up-regulates endogenous TWIST1 mRNA in prostate cancer cells.
Conclusion: Our finding that NKX3-1 represses TWIST1 expression emphasizes the functional importance of NKX3-1 in
regulating TWIST1 expression during prostate cancer progression to metastatic disease.
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Background
Metastasis is the leading cause of morbidity and mortality
among men with prostate cancer (PCa). Metastasis is a
complex multistep process controlled by distinct genes and
signaling pathways in each step. Epithelial-meschencymal
transition (EMT), a critical event for morphogenetic move-
ments during formation of parietal endoderm during gas-
trulation, may represent the initial phase of metastasis.
Furthermore, EMT seems to induce stem-like properties of
epithelial cells [1].
A pivotal step of EMT is the loss of E-cadherin [2].
TWIST1, a master regulator of mesodermal development
and a key mediator in the metastatic process, represses
the expression of E-cadherin [3]. Furthermore, TWIST1
depletion reduces the expression of N-cadherin in PC3
cells, a metastatic prostate cancer cell line, suggesting that
TWIST1 supports EMT in prostate cancer [4]. In support
of this, a positive correlation between the level of TWIST1
and prostate cancer metastasis has been reported [5].
NKX3-1 is a critical gene associated with early stage of
prostate tumorigenesis as down-regulation of NKX3-1 is
observed in both prostatic intraepithelial neoplasia (PIN)
and adenocarsinomas [6]. Whereas high levels of TWIST1
is expressed in prostate cancer metastasis, low levels of
NKX3-1 expression is observed in most prostate cancer
metastasis examined [7]. NKX3-1 encodes a homeobox
gene that is switched on during embryonic development
of prostate tissue and is one of the earliest markers of
luminal prostate epithelium [8]. NKX3-1 expression is
strictly regulated by androgens and also appears to mark
a sub-population of prostate stem cells [9,10].
We report in this paper that TWIST1 is a novel
androgen-regulated gene whose expression is tightly con-
trolled by NKX3-1.
Results
TWIST1 is regulated by androgens
The expression of TWIST1 mRNA increased 4-fold in
LNCaP cells incubated with 0.5 nM R1881 for 72 hours
relative to untreated cells (ctr.) and reached more
than a 10-fold induction at 10 nM R1881 (Figure 1A).
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Corresponding regulation of TWIST1 mRNA was also
demonstrated in RWPE-1, a benign prostate cell line (data
not shown). Up-regulation of TWIST1 expression was
also observed at the protein level in LNCaP cells stimu-
lated with increasing concentrations of R1881 (Figure 1B).
To determine if AR mediates the effect of androgens on
TWIST1 expression, LNCaP cells were transfected with a
siRNA targeting AR (AR) or a non-silencing siRNA as
control (ctr.). Down-regulation of AR expression (Figure 2,
lower panel) reduced the mRNA level of TWIST1 by 80%
relative to control (Figure 2A, upper panel) supporting the
concept that TWIST1 is an AR target gene in LNCaP
cells. Down-regulation of AR also reduced the level of
NKX3-1 (Figure 2, lower panel).
TWIST1 is an NKX3-1 target gene
In an effort to find binding sites for AR (ARE) or
androgen-regulated transcription factors, we examined the
human TWIST1 genomic sequence using MatInspector
[11]. Three putative binding sites for NKX3-1 designated
BS1, BS2 and BS3 (Figure 3A) were identified. In addition
we observed several potential AREs. Chromatin immu-
nopreciptation analyses (ChIP) using chromatin isolated
from LNCaP cells stimulate with 10 nM R1881 (+R1881)
for 24 hours or unstimulated cells as control (−R1881)
resulted in amplification of BS3. We were not able to
detect binding to either BS1 or BS2 (data not shown,
n=3). A 5-fold increase in NKX3-1 binding activity to
the TWIST1 promoter upon R1881 stimulation was
observed (Figure 3B). Additionally, PCR amplification of
non-targeted DNA (genomic contig of chromosome 12)
was used as negative control (data not shown).
Next, a reporter construct containing 5kb of the mouse
TWIST1 promoter (pGL3-TWIST-Luc) was co-transfected
with an NKX3-1 expression vector. Over-expression of
NKX3-1 reduced the promoter activity of TWIST1 by 50%,
indicating that NKX3-1 represses the TWIST1 promoter
activity (Figure 3C). No effect of NKX3-1 over-expression
was observed on cells transfected with pGL3 lacking the
TWIST1 promoter (pGL3).
Finally, the effect of NKX3-1 on endogenous TWIST1
mRNA level was studied by transfecting LNCaP cells with
siRNA targeting NKX3-1. A 5-fold increase in TWIST1
mRNA level was observed when NKX3-1 expression was
down-regulated (Figure 3D). The impact of R1881 stimu-
lation, NKX3-1 overexpression and siRNA on NKX3-1
Figure 1 Androgen up-regulates TWIST1 expression. A. LNCaP cells were stimulated with increasing doses of the synthetic androgen R1881,
and the relative level of TWIST1 compared to LNCaP cells left untreated in charcoal stripped fetal calf serum and phenol red free medium (CSS)
was quantified using sqRT-PCR. Data are presented as mean ± SD (n=3) relative to unstimulated cells (control). A paired t-test was performed and
a two-tailed p-value <0,05 is indicated with a *. B. LNCaP cells were stimulated with increasing doses of the synthetic androgen R1881 or left
untreated in CSS for 3 days before total protein was extracted. A representative Western blot probed with anti human TWIST1 antibody and anti
PRKAR1A antibody as loading control is shown.
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expression in LNCaP cells are summarized in Figure 3E.
Both R1881 stimulation as well as overexpression of
NKX3-1 led to a significant increase in NKX3-1 expres-
sion, while siRNA against NKX3-1 reduced the expression
markedly.
Discussion
In this study we show both that TWIST1 mRNA is
up-regulated by androgen via AR and that NKX3-1, a
well-known androgen-regulated gene, binds the upstream
regulatory region of the TWIST1 gene and represses the
expression of TWIST1.
In a recent study, Takayama et al. [12] identified putative
direct target genes of AR using ChIP-on ChIP and Cap
Analysis Gene Expression (CAGE). One of the genes
identified by in silico analysis was TWIST1. Our results
support this report as increased levels of TWIST1
mRNA was observed in R1881 stimulated LNCaP cells,
while reduced expression of TWISTl was observed in
cells transfected with siRNA targeting AR.
Furthermore, our data shows binding of NKX3-1 to the
promoter region of TWIST1. We therefore suggest that
NKX3-1 mediates an indirect and late effect of androgen
stimulation on TWIST1 expression. Interestingly, we show
that siRNA targeting AR reduces the level of TWIST1,
whereas siRNA targeting NKX3-1 increases TWIST1 ex-
pression suggesting that TWIST1 expression is tightly con-
trolled by androgen. NKX3-1 has been shown to function
both as an activator and a repressor of transcription, but
few target genes have been identified [13-15].
The physical binding of NKX3-1 to the TWIST1 pro-
moter might block the mesenchymal drive of TWIST1,
until NKX3-1 expression is down-regulated or lost in
PIN or adenocarcinoma lesions. Loss of NKX3-1 expres-
sion has been observed in ~20% of PIN lesions, ~40% of
advanced prostate tumors and up to 80% of metastatic
prostate cancer [16]. Androgen deprivation therapy as
the most widely used treatment for advanced prostate
cancer is likely to abolish androgen-stimulation of NKX3-1,
leading eventually to down-regulation of repressor protein
and de-repression of TWIST1’s metastatic potential.
In an attempt to identify genes whose regulation are
altered by NKX3-1, Song et al. [17] performed gene expres-
sion profiling analyses on micro dissected glands from
NKX3-1-deficient prostate tissues during prostate cancer
progression. They observed similarities between the expres-
sion profile of the micro dissected glands and constitutive
activated AKT-transgenic mice as well as PTEN-deficient
mice, suggesting that the PTEN-AKT-NKX3-1 axis
serve as a major molecular path of prostate tumori-
genesis. Li and Zhou [18] showed that activation of
the AKT pathway by TWIST1 is critical for the sus-
tention of cancer stem cell-like traits generated by
EMT, again suggesting a link between loss of NKX3-1
expression, relive of TWIST1 expression and eventually
activation of AKT pathway.
Conclusions
We report in this paper that TWIST1 is an androgen-
regulated gene, tightly regulated by NKX3-1. We show
that NKX3-1 binds to the TWIST1 promoter and that
NKX3-1 over-expression reduces the activity of a TWIST1
promoter reporter construct, whereas NKX3-1 siRNA up-
regulated endogenous TWIST1 mRNA in prostate cancer
Figure 2 AR mediates the effect of androgen on TWIST1
expression. LNCaP cells cultured in RPMI medium containing 10%
FCS were transfected with 100 nM of siRNA against AR (AR) or a
non-silencing control (ctr.) siRNA. Total RNA and protein was
harvested at 48 h after transfection. Upper panel: TWIST1 mRNA
expression was examined using sqRT-PCR. Data are presented as
mean ± SD (n=3) relative to the levels of LNCaP cells transfected
with a non-silencing control siRNA. A paired t-test was performed
and a two-tailed p value <0,05 is indicated with a *. Lower panel:
Representative Western blots of TWIST1, AR, NKX3-1 and α-tubulin
(loading control) are shown.
Eide et al. Cancer Cell International 2013, 13:4 Page 3 of 6
http://www.cancerci.com/content/13/1/4
Figure 3 (See legend on next page.)
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cells. Our finding that NKX3-1 represses TWIST1 expres-
sion emphasizes the functional importance of NKX3-1
in regulating TWIST1 expression during prostate cancer
progression to metastatic disease.
Methods
Cell culture
LNCaP and RWPE-1 cells were purchased from ATCC
(Rockville, MD) and cultured in RPMI 1640 medium
containing 10% fetal calf serum (FCS) or Keratinocyte-
SFM medium from Invitrogen (Carlsbad, CA, USA) sup-
plemented with 2.5 μg Epidermal Growth Factor (EGF)
and 25 mg Bovine Pituitary Extract (BPE), respectively,
and stimulation with synthetic androgen R1881 was per-
formed as previously described [19].
Semi-quantitative real time RT-PCR (sqRT-PCR)
Total RNA was isolated using Trizol™ from Invitrogen
(Carlsbad, CA), and 100 ng of total RNA was used in a
one-step RT-PCR reaction (QIAGEN Quantitect SYBR
Green RT-PCR kit) that was performed using an MJ Re-
search DNA Engine Opticon Continuous Fluorescence
Detection System (MJ Research Inc., Waltham, MA). RT-
PCR cycles were performed as previously described by
Ramberg et al. [20]. G6PD was used for normalization.
The ΔΔCt formula was used as described in the protocol
from Applied Biosystems (Foster City, CA). All the PCR-
products were verified by sequencing.
Primer sets used in sqRT-PCR
G6PD (NM_000402); Left: tgcatgagccagataggc and
right: acagggaggagatgtggttg, NKX3-1 (NM_006167);
Left: gagacgctggcagagacc and right: ttctgcggctgcttaggg,
AR (NM_000044); Left: gcgatccttcaccaatgtca and right:
cattcggacacactggctgt, TWIST1 (NM_000474); Left: cttc
tcggtctggaggatgg and right: ctccttctctggaaacaatgaca.
Immunoblotting
Protein extraction followed by Western blot analysis was
performed as previously described by Kvissel et al. [19]. Pri-
mary antibodies used were the following: anti-TWIST1
(H-81, sc-15393), anti-AR (N-20, sc-816), both from Santa
Cruz Biotechnology (Santa Cruz, CA). The anti-NKX3-1
antibody was kindly provided by Professor Fahri Saatcioglu
at Department of Molecular Biosciences, University of
Oslo, Norway. For loading control we used anti-PRKAR1A
(610609, BD Transduction Laboratories) or anti-α-tubulin
antibody from Sigma (St. Louis, MO).
Transfection and luciferase assay
LNCaP cells were cultured at 300.000 cells per 6-well
dish and transfected with a luciferase reporter plasmid
including 5 kb of the mouse TWIST1 promoter- pGL3-
TWIST (kindly provided by Steven Kendall and Carlotta
Glackin, Beckman Research Institute, City of Hope, USA)
or pGL3 as negative control using Lipofectamine 2000
(INVT11668019, Invitrogen) according to the manu-
factures protocol. For overexpression of NKX3-1, a
commercial transfection-ready TRUE clone (sc116287,
ORIGENE, Rockville, MD, USA) was purchased. Cells
were co-transfected with pCMV β-gal (Clontech) to
monitor the transfection efficiency. After 72 hours,
luciferase and β-galactosidase activity were measured
as previously described [20].
Preparation and transfection of synthetic small interfering
RNA (siRNA)
siRNA targeting the following sequence within the an-
drogen receptor mRNA: 5’-AAAAGCCCATCGTAGAG
GCCCCA-3’ was purchased from Dharmacon (Dharmacon
Inc. (Lafayette, CO). A non-silencing siRNA (cat.no
D-001810-10-20, Dharmacon) was included in all siRNA
experiments. siRNA against NKX3-1 was purchased from
QIAGEN (2-for-silencing) and included the following
sequences: NKX3-1-1: 5’-CAGGCTATCATATATACTGTA
-3’, NKX3-1-2: 5’-ACGCTATAAGACTAAGCGAAA-3’.
(See figure on previous page.)
Figure 3 NKX3-1 mediates androgen-regulation of TWIST1. A. Three putative NKX3-1-bindingsites (BS1, BS2 and BS3) are shown as boxes in
the TWIST1 promoter (from NCBI MapViewer). B. Chromatin immunoprecipitation was performed using chromatin isolated from LNCaP cells
stimulate with 10 nM R1881 (+R1881) for 24 hours or left untreated (−R1881) and using a monoclonal antibody against NKX3-1 (NKX3-1). sqPCR
results using primers targeting BS3 are shown in B. The results of the BS3 primer set are shown adjusted to the levels of chromatin
immunoprecipitated with IgG as a negative control. Data are presented as mean ± SD (n=3). C. LNCaP cells were transfected with pGL3-TWIST-Luc
(pGL3-TWIST) and a human NKX3-1 expression plasmid or an empty vector (pCR3) as well as pCMV β-gal. As control, LNCaP cells were transfected with
a reporter plasmid lacking the TWIST promoter region (pGL3) and the human NKX3-1 expression vector or an empty expression plasmid (pCR3). The
luciferase activities were normalized against the corresponding β-galactosidase activities and the results are shown as mean ± SD (n=3). A paired t-test
was performed and a two-tailed p value <0,05 is indicated with a * D. LNCaP cells were transfected with 100 nM of siRNA targeting NKX3-1 or a non-
silencing siRNA (ctr.) and total RNA was harvested 72 hours after transfection. TWIST1 mRNA expression was examined using sqRT-PCR. The data are
shown as mean ± SD (n=3) relative to the levels of LNCaP cells transfected with a non-silencing control siRNA. E. Representative Western blots
showing expression levels of NKX3-1 in (from top) LNCaP cells stimulated with 10 nM of R1881, transfected with NKX3-1 overexpression vector or
targeted by siRNA against NKX3-1. α-tubulin is shown as loading control.
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All siRNAs were transfected into cells using Dharma-
FECT ™ 3 transfection reagent according to the manu-
facture’s protocol (cat.no T-2003, Dharmacon).
Chromatin immunoprecipitation
ChIP assays were carried out according to the QuickChIP
protocol (Imgenex, San Diego, CA) with a crosslinking
time of 10 minutes using 1% formaldehyde for the LNCaP
cells and using an anti human NKX3-1 monoclonal
antibody (cat.no 35–9700, Zymed Laboratories Inc., San
Fransisco, CA). Following DNA purification (QuickChIP
DNA Purification kit), sqPCR was performed using
QIAGEN Quantitect SYBR Green RT-PCR kit with
the following primers:
NKX3-1 BS3; Left: cccagttacacttggatgcagta and right:
tcccctggtgagatcatacatac. Negative control primers from
human chromosome 12 genomic contig; Left: atggttgc
cactggggatct and right: tgccaaagcctaggggaaga. Chromatin
immunoprecipitated with IgG was used as a negative
control. The ΔΔCt formula was used as described in the
protocol from Applied Biosystems (Foster City, CA).
Abbrevations
PCa: Prostate Cancer; EMT: Epithelial-Meschencymal Transition; PIN: Prostatic
Intraepithelial Neoplasia; AR: Androgen Receptor; ChIP: Chromatin
Immunopreciptation Analyses.
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